News
2d
Clinical Trials Arena on MSNAstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trialThe trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.
The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...
AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...
AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...
AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...
Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.
Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
Pharma giant AstraZeneca has reported positive results from a Phase III trial of its treatment for non-muscle-invasive ...
Imjudo plus Imfinzi has also been filed for approval in Europe, Japan, and several other countries, said AZ in a statement. AstraZeneca's run of positive trial results with its cancer therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results